[1]
|
Burch, J. and Ahmad, I. (2020) Cancer, Gastrointestinal Stromal (GIST). StatPearls, Treasure Island.
|
[2]
|
Costa, P.A., Hana, C.K.A., Balaji, N.C., Skryd, A.F., Valdes, B.N., Minjares, R.O., Barreto-Coelho, P., Espejo-Freire, A.P., Hakim, M.O., Jonczak, E., et al. (2021) Dose Escalation of Ripretinib Can Lead to Response in Advanced Gastrointestinal Stro-mal Tumor Patients Refractory to the Standard Dose: A Report of Two Cases. Gastrointest Stromal Tumor, 4, 1-8. https://doi.org/10.21037/gist-21-1
|
[3]
|
Nishida, T., Blay, J.-Y., Hirota, S., Kitagawa, Y. and Kang, Y.-K. (2016) The Standard Diagnosis, Treatment, and Follow-up of Gastrointestinal Stromal Tumors Based on Guidelines. Gastric Cancer, 19, 3-14.
https://doi.org/10.1007/s10120-015-0526-8
|
[4]
|
Demetri, G.D., Von Mehren, M., Antonescu, C.R., DeMatteo, R.P., Ganjoo, K.N., Maki, R.G., Pisters, P.W., Raut, C.P., Riedel, R.F., Schuetze, S., et al. (2010) NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. Journal of the National Compre-hensive Cancer Network, 8, S1-S44.
https://doi.org/10.6004/jnccn.2010.0116
|
[5]
|
Kindblom, L.G., Remotti, H.E., Aldenborg, F. and Meis-Kindblom, J.M. (1998) Gastrointestinal Pacemaker Cell Tumor (GIPACT): Gastroin-testinal Stromal Tumors Show Phenotypic Characteristics of the Interstitial Cells of Cajal. The American Journal of Pathology, 152, 1259-1269.
|
[6]
|
Reichardt, P. (2018) The Story of Imatinib in GIST—A Journey Through the Development of a Targeted Therapy. Oncology Research and Treatment, 41, 472-477. https://doi.org/10.1159/000487511
|
[7]
|
Poveda, A., García Del Muro, X., López-Guerrero, J.A., Cubedo, R., Martínez, V., Romero, I., et al. (2017) GEIS Guidelines for Gastrointestinal Sarco-mas (GIST). Cancer Treatment Reviews, 55, 107-119.
https://doi.org/10.1016/j.ctrv.2016.11.011
|
[8]
|
Falkenhorst, J., Hamacher, R. and Bauer, S. (2019) New Therapeu-tic Agents in Gastrointestinal Stromal Tumours. Current Opinion in Oncology, 31, 322-328. https://doi.org/10.1097/CCO.0000000000000549
|
[9]
|
Serrano, C., Mariño-Enríquez, A., Tao, D.L., Ketzer, J., Ei-lers, G., Zhu, M., Yu, C., et al. (2019) Complementary Activity of Tyrosine Kinase Inhibitors against Secondary Kit Mutations in Imatinib-Resistant Gastrointestinal Stromal Tumours. British Journal of Cancer, 120, 612-620. https://doi.org/10.1038/s41416-019-0389-6
|
[10]
|
Demetri, G.D., van Oosterom, A.T., Garrett, C.R., Blackstein, M.E., Shah, M.H., Verweij, J., et al. (2006) Efficacy and Safety of Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumour after Failure of Imatinib: A Randomised Controlled Trial. Lancet, 368, 1329-1338. https://doi.org/10.1016/S0140-6736(06)69446-4
|
[11]
|
Demetri, G.D., Reichardt, P., Kang, Y.K., Blay, J.Y., Rutkowski, P., Gelderblom, H., et al. (2013) Efficacy and Safety of Regorafenib for Advanced Gastrointestinal Stromal Tumours after Failure of Imatinib and Sunitinib (GRID): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet, 381, 295-302.
https://doi.org/10.1016/S0140-6736(12)61857-1
|
[12]
|
Martín-Broto, J., Rubio, L., Alemany, R. and López-Guerrero, J.A. (2010) Clinical Implications of KIT and PDGFRA Genotyping in GIST. Clinical and Translational Oncology, 12, 670-676. https://doi.org/10.1007/s12094-010-0576-7
|
[13]
|
Brčić, I., Argyropoulos, A. and Liegl-Atzwanger, B. (2021) Update on Molecular Genetics of Gastrointestinal Stromal Tumors. Diagnostics, 11, Article No. 194. https://doi.org/10.3390/diagnostics11020194
|
[14]
|
Akcakaya, P., Caramuta, S., Ahlen, J., Ghaderi, M., Berglund, E., et al. (2014) MicroRNA Expression Signatures of Gastrointestinal Stromal Tumours: Associations with Imatinib Resistance and Patient Outcome. British Journal of Cancer, 111, 2091-2102. https://doi.org/10.1038/bjc.2014.548
|
[15]
|
Esteller, M. (2011) Cancer Epigenetics for the 21st Century: What’s Next? Genes & Cancer, 2, 604-606.
https://doi.org/10.1177/1947601911423096
|
[16]
|
Niinuma, T., Suzuki, H. and Sugai, T. (2018) Molecular Charac-terization and Pathogenesis of Gastrointestinal Stromal Tumor. Translational Gastroenterology and Hepatology, 3, Arti-cle No. 2. https://doi.org/10.21037/tgh.2018.01.02
|
[17]
|
Saito, K., Sakurai, S., Sano, T., Sakamoto, K., Asao, T., Hosoya, Y., et al. (2008) Aberrant Methylation Status of Known Methylation-Sensitive CpG Islands in Gastrointestinal Stromal Tumors without Any Correlation to the State of C-Kit and PDGFRA Gene Mutations and Their Malignancy. Cancer Science, 99, 253-259.
https://doi.org/10.1111/j.1349-7006.2007.00682.x
|
[18]
|
Daniel, F.I., Cherubini, K., Yurgel, L.S., De Figueiredo, M.A. and Salum, F.G. (2011) The Role of Epigenetic Transcription Repression and DNA Methyltransferases in Cancer. Cancer, 117, 677-687.
https://doi.org/10.1002/cncr.25482
|
[19]
|
Sioulas, A.D., Vasilatou, D., Pappa, V., Dimitriadis, G. and Triantafyllou, K. (2013) Epigenetics in Gastrointestinal Stromal Tumors: Clinical Implications and Potential Therapeuticperspectives. Digestive Diseases and Sciences, 58, 3094-3102. https://doi.org/10.1007/s10620-013-2785-8
|
[20]
|
Nannini, M., Ravegnini, G., Angelini, S., Astolfi, A., Biasco, G. and Pantaleo, M.A. (2015) miRNA Profiling in Gastrointestinal Stromal Tumors: Implication as Diagnostic and Prognostic Markers. Epigenomics, 7, 1033-1049.
|
[21]
|
Szucs, Z., Thway, K., Fisher, C., Bulusu, R., Constantinidou, A., Benson, C., et al. (2017) Molecular Subtypes of Gastrointestinal Stromal Tumors and Their Prognostic and Therapeutic Implications. Future Oncology, 13, 93-107.
https://doi.org/10.2217/fon-2016-0192
|
[22]
|
Lasota, J. and Miettinen, M. (2008) Clinical Significance of Oncogenic KIT and PDGFRA Mutations in Gastrointestinal Stromal Tumours. Histopathology, 53, 245-266. https://doi.org/10.1111/j.1365-2559.2008.02977.x
|
[23]
|
Martín, J., Poveda, A,. Llombart-Bosch, A., Ramos, R., López-Guerrero, J.A., García del Muro, J., et al. (2005) Deletions Affecting Codons 557-558 of Thec-KIT Gene Indicate a Poor Prognosis in Patients with Completelyresected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS). Journal of Clinical Oncology, 23, 6190-6198. https://doi.org/10.1200/JCO.2005.19.554
|
[24]
|
Martin-Broto, J., Gutierrez, A., Garcia-del-Muro, X., Lopez-Guerrero, J.A., Martinez-Trufero, J., de Sande, L.M., et al. (2010) Prognostic Time Dependence of Deletions Af-fecting Codons 557 and/or 558 of KIT Gene for Relapse-free Survival (RFS) in Localized GIST: A Spanish Group for Sarcoma Research (GEIS) Study. Annals of Oncology, 21, 1552-1557. https://doi.org/10.1093/annonc/mdq047
|
[25]
|
Wozniak, A., Rutkowski, P., Schöffski, P., Ray-Coquard, I., Hostein, I., Schildhaus, H.U., et al. (2014) Tumour Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumours of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. Clinical Cancer Re-search, 20, 6105-6116.
https://doi.org/10.1158/1078-0432.CCR-14-1677
|
[26]
|
Wozniak, A., Rutkowski, P., Piskorz, A., Ciwoniuk, M., Osuch, C., Bylina, E., et al. (2012) Polish Clinical GIST Registry. Prognostic Value of KIT/PDGFRA Mutations in Gastrointestinal Stromal Tumours (GIST): Polish Clinical GIST Registry Experience. Annals of Oncology, 23, 353-360. https://doi.org/10.1093/annonc/mdr127
|
[27]
|
Steigen, S.E., Eide, T.J., Wasag, B., Lasota, J. and Miettinen, M. (2007) Mutations in Gastrointestinal Stromal Tumours—A Population-Based Study from Northern Norway. APMIS, 115, 289-298.
https://doi.org/10.1111/j.1600-0463.2007.apm_587.x
|
[28]
|
Yuzawa, S., Opatowsky, Y., Zhang, Z., Mandiyan, V., Lax, I. and Schlessinger, J. (2007) Structural Basis for Activation of Thereceptor Tyrosine Kinase KIT by Stem Cell Factor. Cell, 130, 323-334.
https://doi.org/10.1016/j.cell.2007.05.055
|
[29]
|
Antonescu, C.R., Sommer, G., Sarran, L., Tschernyavsky, S.J., Riedel, E., Woodruff, J.M., et al. (2003) Association of KIT Exon 9 Mutations with Nongastric Primary Site and Ag-gressive Behaviour: KIT Mutation Analysis and Clinical Correlates of 120 Gastrointestinal Stromal Tumours. Clinical Cancer Research, 9, 3329-3337.
|
[30]
|
Lasota, J., Corless, C.L., Heinrich, M.C., Debiec-Rychter, M., Sciot, R., Wardelmann, E., et al. (2008) Clinico-Pathologic Profile of Gastrointestinal Stromal Tumours (GISTs) with Primary KIT Exon 13 or Exon 17 Mutations: A Multicenter Study on 54 Cases. Clinical Cancer Research, 21, 476-484. https://doi.org/10.1038/modpathol.2008.2
|
[31]
|
Corless, C.L., Barnett, C.M. and Heinrich, M.C. (2011) Gastroin-testinal Stromal Tumours: Origin and Molecular Oncology. Nature Reviews Cancer, 11, 865-878. https://doi.org/10.1038/nrc3143
|
[32]
|
Lasota, J., Stachura, J. and Miettinen, M. (2006) GISTs with PDGFRA Exon 14 Mutationsrepresent Subset of Clinically Favorable Gastric Tumors with Epithelioid Morphology. Laboratory Investi-gation, 86, 94-100.
https://doi.org/10.1038/labinvest.3700360
|
[33]
|
Miettinen, M., Fetsch, J.F., Sobin, L.H. and Lasota, J. (2006) Gas-trointestinal Stromal Tumors in Patients with Neurofibromatosis 1: A Clinicopathologic and Molecular Genetic Study of 45 Cases. The American Journal of Surgical Pathology, 30, 90-96. https://doi.org/10.1097/01.pas.0000176433.81079.bd
|
[34]
|
Burgoyne, A.M., De Siena, M., Alkhuziem, M., Tang, C.M., Medina, B., Fanta, P.T., Belinsky, M.G., Von Mehren, M., Thorson, J.A., Madlensky, L., et al. (2017) Duode-nal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic Nf1 and Notch Pathway Mutations. JCO Precision Oncology, 1, 1-12. https://doi.org/10.1200/PO.17.00014
|
[35]
|
Hostein, I., Faur, N., Primois, C., Boury, F., Denard, J., Emile, J.F., Bringuier, P.P., Scoazec, J.Y. and Coindre, J.M. (2010) BRAF Mutation Status in Gastrointestinal Stromal Tumors. American Journal of Clinical Pathology, 133, 141-188. https://doi.org/10.1309/AJCPPCKGA2QGBJ1R
|
[36]
|
Falchook, G.S., Trent, J.C., Heinrich, M.C., Beadling, C., Patterson, J., Bastida, C.C., Blackman, S.C. and Kurzrock, R. (2013) BRAF Mutant Gastrointestinal Stromal Tumor: First Report of Regression with BRAF Inhibitor Dabrafenib (gsk2118436) and Whole Exomic Sequencing for Analysis of Acquired Resistance. Oncotarget, 4, 310-315.
https://doi.org/10.18632/oncotarget.864
|
[37]
|
Miranda, C., Nucifora, M., Molinari, F., Conca, E., Anania, M.C., Bordoni, A., et al. (2012) KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 18, 1769-1776. https://doi.org/10.1158/1078-0432.CCR-11-2230
|
[38]
|
Osaki, M., Oshimura, M. and Ito, H. (2004) PI3K-Akt Pathway: Its Functions and Alterations in Human Cancer. Apoptosis, 9, 667-676. https://doi.org/10.1023/B:APPT.0000045801.15585.dd
|
[39]
|
Lasota, J., Felisiak-Golabek, A., Wasag, B., Kowalik, A., Zięba, S., Chłopek, M., Wang, Z.F., Coates, T., Kopczynski, J., Gozdz, S., et al. (2016) Frequency and Clinicopathologic Profile of Pik3ca Mutant Gists: Molecular Genetic Study of 529 Cases. Modern Pathology, 29, 275-282. https://doi.org/10.1038/modpathol.2015.160
|
[40]
|
Zhang, L., Smyrk, T.C., Young Jr., W.F., Stratakis, C.A. and Carney, J.A. (2010) Gastric Stromal Tumors in Carney Triad Aredifferent Clinically, Pathologically, and Be-haviorally from Sporadicgastric Gastrointestinal Stromal Tumors: Findings in 104 Cases. The American Journal of Sur-gical Pathology, 34, 53-56.
https://doi.org/10.1097/PAS.0b013e3181c20f4f
|
[41]
|
Haller, F., Moskalev, E.A., Faucz, F.R., Barthelmeß, S., Wiemann, S., Bieg, M., Assie, G., Bertherat, J., Schaefer, I.M., Otto, C., et al. (2014) Aberrant DNA Hypermethylation of SDHC: A Novel Mechanism of Tumor Development in Carney Triad. Endocrine-Related Cancer, 21, 567-577. https://doi.org/10.1530/ERC-14-0254
|
[42]
|
Miettinen, M., Killian, J.K., Wang, Z.F., Lasota, J., Lau, C., Jones, L., et al. (2013) Immunohistochemical Loss of Succinate Dehydrogenase Subunit a (SDHA) in Gastrointestinal Stromal Tu-mors (GISTs) Signals SDHA Germline Mutation. The American Journal of Surgical Pathology, 37, 234-240. https://doi.org/10.1097/PAS.0b013e3182671178
|
[43]
|
Deaton, A.M. and Bird, A. (2011) CpG Islands and the Regulation of Transcription. Genes & Development, 25, 1010-1022. https://doi.org/10.1101/gad.2037511
|
[44]
|
Choi, S.H., Worswick, S., Byun, H.M., Shear, T., Soussa, J.C., Wolff, E.M., et al. (2009) Changes in DNA Methylation of Tandem DNA Repeats Are Different from Interspersed Repeats in Cancer. International Journal of Cancer, 125, 723-729. https://doi.org/10.1002/ijc.24384
|
[45]
|
Liu, Y., Tseng M., Perdreau, S.A., Rossi, F., Antonescu, C., Besmer, P., et al. (2007) Histone H2AX Is a Mediator of Gastrointestinal Stromal Tumor Cell Apoptosis Following Treatment with Imatinib Mesylate. Cancer Journals, 67, 2685-2692. https://doi.org/10.1158/0008-5472.CAN-06-3497
|
[46]
|
Liu, S., Liao, G., Ding, J., Ye, K., Zhang, Y., Zeng, L., et al. (2014) Dysregulated Expression of Snail and E-Cadherin Correlates with Gastrointestinal Stromal Tumor Metastasis. European Journal of Cancer Prevention, 23, 329-335.
https://doi.org/10.1097/CEJ.0000000000000072
|
[47]
|
Schneider-Stock, R., Boltze, C., Lasota, J., Peters, B., Cor-less, C.L., Ruemmele, P., et al. (2005) Loss of P16 Protein Defines High-Risk Patients with Gastrointestinal Stromal Tumors: A Tissue Microarray Study. Clinical Cancer Research, 11, 638-645. https://doi.org/10.1158/1078-0432.638.11.2
|
[48]
|
Yang, J., Ikezoe, T., Nishioka, C., Takezaki, Y., Hanazaki, K., Taguchi, T., et al. (2012) Long-Term Exposure of Gastrointestinal Stromal Tumor Cells to Sunitinib Induces Epigenetic Silencing of the PTEN Gene. International Journal of Cancer, 130, 959-966. https://doi.org/10.1002/ijc.26095
|
[49]
|
Bauer, S., Duensing, A., Demetri, G.D. and Fletcher, J.A. (2007) KIT On-cogenic Signaling Mechanisms in Imatinib-Resistant Gastrointestinal Stromal Tumor: PI3-Kinase/AKT Is a Crucial Sur-vival Pathway. Oncogene, 26, 7560-7568. https://doi.org/10.1038/sj.onc.1210558
|
[50]
|
Huang, K.K., McPherson, J.R., Tay, S.T., Das, K., Tan, I.B., Ng, C.C., et al. (2016) SETD2 Histone Modifier Loss in Aggressive GI Stromal Tu-mours. Gut, 65, 1960-1972. https://doi.org/10.1136/gutjnl-2015-309482
|
[51]
|
Sweatt, J.D., Nestler, E.J., Meaney, M.J. and Akbarian, S. (2013) An Overview of the Molecular Basis of Epigenetics.. In: Sweatt, J.D., Nestler, E.J., Mea-ney, M.J. and Akbarian, S., Eds., Epigenetic Regulation in the Nervous System. Basic Mechanisms and Clinical Impact, Academic Press, Cambridge, 3-33.
https://doi.org/10.1016/B978-0-12-391494-1.00001-X
|
[52]
|
Niinuma, T., Suzuki, H., Nojima, M., Nosho, K., Yamamoto, H., Takamaru, H., et al. (2012) Upregulation of MiR-196a and HOTAIR Drive Malignant Character in Gas-trointestinal Stromal Tumors. Cancer Research, 72, 1126-1136. https://doi.org/10.1158/0008-5472.CAN-11-1803
|
[53]
|
Hajjari, M. and Salavaty, A. (2015) HOTAIR: An Onco-genic Long Non-Coding RNA in Different Cancers. Cancer Biology & Medicine, 12, 1-9.
|